Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 83Recruiting 35Active not recruiting 33Terminated 25Unknown 8Withdrawn 4Not yet recruiting 4Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1FED 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4mCRPC 1Neoplasm Metastasis 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

Androgen Antagonists 10darolutamide 6Magnetic Resonance Spectroscopy 6apalutamide 5Docetaxel 5enzalutamide 4Specimen Handling 4Radiotherapy 4Radiosurgery 4Abiraterone Acetate 4Electroacupuncture 3Brachytherapy 3pembrolizumab 2bicalutamide 2Standard of Care 2Resistance Training 2Radiation 2Prednisone 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × enzalutamide × Clear all
NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT06430411 2024-05-28

OLIGOMET

Medical University of Vienna

Not yet recruiting
500 enrolled
Genitourinary

Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡